GV — Genomic Vision SA Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -788.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1.11 | 1.77 | 1.08 | 0.99 | 1.03 | n/a | n/a | -13.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genomic Vision SA is a France-based biotechnology company. It develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The Company uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. It develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
Directors
- Dominique Remy-Renou CMG
- Elisabeth Ourliac NEC
- Aaron Bensimon CEO
- Stephane Verdood VSU
- Jerome Vailland CFO
- Mark Lynch DSL
- Thierry Huet OTH
- Tamar Saraga IND
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- July 5th, 2004
- Public Since
- April 2nd, 2014
- No. of Employees
- 37
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 385,105,997
- Address
- Green Square Batiment E, BAGNEUX, 92220
- Web
- http://www.genomicvision.com
- Phone
- +33 149080740
- Contact
- Jerome Vailland
- Auditors
- RSM Paris
Upcoming Events for GV
Half Year 2024 Genomic Vision SA Earnings Release
Similar to GV
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
What is the Genomic Vision SA share price?
As of Today at 18:09 UTC, shares in Genomic Vision SA are trading at €0.00. This share price information is delayed by 15 minutes.
How has the Genomic Vision SA share price performed this year?
Shares in Genomic Vision SA last closed at €0.00 and the price had moved by -97.81% over the past 365 days. In terms of relative price strength the Genomic Vision SA share price has underperformed the FTSE Global All Cap Index by -97.92% over the past year.
What are the analyst and broker recommendations for Genomic Vision SA?
The overall consensus recommendation for Genomic Vision SA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genomic Vision SA dividend yield?
Genomic Vision SA does not currently pay a dividend.
Does Genomic Vision SA pay a dividend?
Genomic Vision SA does not currently pay a dividend.
When does Genomic Vision SA next pay dividends?
Genomic Vision SA does not currently pay a dividend.
How do I buy Genomic Vision SA shares?
To buy shares in Genomic Vision SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genomic Vision SA?
As of the previous close price of €0.00, shares in Genomic Vision SA had a market capitalisation of .
Where are Genomic Vision SA shares listed?
Here are the trading details for Genomic Vision SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: GV
What kind of share is Genomic Vision SA?
Based on an overall assessment of its quality, value and momentum Genomic Vision SA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genomic Vision SA share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Genomic Vision SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genomic Vision SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -90.41%.
As of the last closing price of €0.00, shares in Genomic Vision SA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genomic Vision SA PE Ratio?
The Genomic Vision SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genomic Vision SA?
Genomic Vision SA's management team is headed by:
- Dominique Remy-Renou - CMG
- Elisabeth Ourliac - NEC
- Aaron Bensimon - CEO
- Stephane Verdood - VSU
- Jerome Vailland - CFO
- Mark Lynch - DSL
- Thierry Huet - OTH
- Tamar Saraga - IND